$CLLS News

Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026

Monthly information on share capital and company voting rights

Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?

Cellectis: An 'All Or Nothing' Pivot To In-Vivo Gene Editing Is Worth Monitoring

Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3

Wells Fargo Maintains Equal-Weight on Cellectis, Lowers Price Target to $3

Baird Maintains Outperform on Cellectis, Lowers Price Target to $8

Citizens Downgrades Cellectis to Market Perform

Cellectis Announces In Vivo Gene Editing Transformation, Exits Lasme-cel and Eti-cel Development

Cellectis S.A. (CLLS) Discusses Strategic Transformation and In Vivo Gene Editing Pipeline Update Transcript

Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

Cellectis Exits Lasme-Cel And Eti-Cel Development To Focus On In Vivo Gene Editing Pipeline, Targeting Cash Runway Extension Into H2 2028

Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update

Monthly information on share capital and company voting rights

Cellectis Announces Participation in Upcoming Investor Conferences

Cellectis: 'Hold' On Lasme-Cel Q4 2026 Catalyst And Eti-Cel Backup Candidate

Cellectis Reports Financial Results for the Second Quarter 2026

Cellectis Q2 Adj. EPS $(0.19) Beats $(0.27) Estimate, Sales $6.904M Miss $13.225M Estimate

Cellectis to Report Second Quarter Financial Results on August 6, 2026